Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2026-01-22 00:00:00 ET · period of report 2026-01-20 · accession 0001193125-26-019686 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-01-22 | 2026-01-20+ | NAMS | Somaiya Mayur Ian | CFO | M - OptEx | $9.26 | +100.0K | 98.2K | New | +$926.0K |
| DMT | 2026-01-22 | 2026-01-20+ | NAMS | Somaiya Mayur Ian | CFO | S - Sale+OE | $32.61 | -100.0K | 117.7K | -46% | -$3.26M |
| DMT | 2026-01-22 | 2026-01-20+ | NAMS | Somaiya Mayur Ian | CFO | M - OptEx | $0.00 | -100.0K | 702.6K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-01-20 | M | A | 60,216 | $9.26 | 118,598 | D | — | — | |
| 2 | Common | Ordinary Shares | 2026-01-21 | S | D | 24,362 | $33.80 | 58,382 | D | — | — | (F6) These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 3 | Common | Ordinary Shares | 2026-01-21 | S | D | 15,422 | $33.25 | 82,744 | D | — | — | (F5) These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 4 | Common | Ordinary Shares | 2026-01-21 | M | A | 39,784 | $9.26 | 98,166 | D | — | — | |
| 5 | Common | Ordinary Shares | 2026-01-20 | S | D | 19,604 | $32.38 | 58,382 | D | — | — | (F4) These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 6 | Common | Ordinary Shares | 2026-01-20 | S | D | 39,712 | $31.78 | 77,986 | D | — | — | (F3) These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 7 | Common | Ordinary Shares | 2026-01-20 | S | D | 900 | $30.64 | 117,698 | D | — | — | (F2) These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| 8 | Derivative | Option (Right to Buy) | 2026-01-21 | M | D | 39,784 | $0.00 | 662,814 | D | $9.26 · — to 2033-11-01 | 39,784 Ordinary Shares | (F7) The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 9 | Derivative | Option (Right to Buy) | 2026-01-20 | M | D | 60,216 | $0.00 | 702,598 | D | $9.26 · — to 2033-11-01 | 60,216 Ordinary Shares | (F7) The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |